Corneal neovascularization inhibition

Sikder, S., Herretes, S.P., Gehlbach, P, Gurewitsch, E., Behrens, A. Topical human amniotic inhibition of induced corneal neovascularization. ARVO Abstracts No 1650 Fort Lauderdale ARVO meeting 2006. 

Yu, W.Z., et al. 2003. Gene transfer of kringle 5 of plasminogen by electroporation inhibits corneal neovascularization. Ophthalmic Res 35 239. 

Li WW, Casey R, Gonzalez EM, Folkman J. Angiostatic steroids potentiated by sulfated cyclodextrins inhibit corneal neovascularization. Invest Ophthalmol Vis Sci 1991 32 2898-2905. 

BenEzra D, Griffin BW, Maftzir G, et al. Topical formulations of novel angiostatic steroids inhibit rabbit corneal neovascularization. Invest Ophthalmol Vis Sci 1997 ... 

Lai CM, Spilsbury K, Brankov M, Zaknich T, Rakoczy PE. Inhibition of corneal neovascularization by recombinant adenovirus mediated antisense VEGF RNA. Exp Eye Res 2002 75 625-634. 

Mwaikambo, B.R. et al. Activation of CD36 inhibits and induces regression of inflammatory corneal neovascularization. Invest Ophthalmol. Vis. Sci. 47 (2006) 4356-64. 

In addition to the work presented here, several alternative viral-vectored approaches have been reported recently. An adeno-associated viral vector (AAV) encoding the soluble VEGF receptor 1, sFlt-1, shows promise for long-term inhibition of two types of ocular neovascularization (Lai et al., 2002). This vector, when injected into the anterior chamber, resulted in expression in both the corneal endothelium and iris pigment epithelium and reduced corneal NV by 36%. Subretinal injection of the same vector reduced choroidal NV subsequent to laser lesions around the optic nerve. These results suggest that a secretable factor expressed in one or more transduced cell populations can be elfective in the control of ocular NV occurring in a disparate cell population. 

---